Form 8-K - Current report:
SEC Accession No. 0001193125-25-096692
Filing Date
2025-04-25
Accepted
2025-04-25 16:01:13
Documents
13
Period of Report
2025-04-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d898205d8k.htm   iXBRL 8-K 25453
  Complete submission text file 0001193125-25-096692.txt   151109

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vor-20250422.xsd EX-101.SCH 2835
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vor-20250422_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vor-20250422_pre.xml EX-101.PRE 11698
15 EXTRACTED XBRL INSTANCE DOCUMENT d898205d8k_htm.xml XML 3767
Mailing Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140
Business Address 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580
Vor Biopharma Inc. (Filer) CIK: 0001817229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39979 | Film No.: 25873636
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)